Megan E McCool1, Andrea Zuelke2, Melissa A Theurich3, Helge Knuettel4, Cristian Ricci5, Christian Apfelbacher5. 1. Medical Sociology, Department of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany. Electronic address: megan.mccool@klinik.uni-regensburg.de. 2. Medical Sociology, Department of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany; Institute of Sociology, Friedrich Schiller University of Jena, Jena, Germany. 3. Metabolic and Nutritional Medicine, Dr von Hauner Children's Hospital, Ludwig Maximilians University of Munich, Munich, Germany. 4. University Library of Regensburg Regensburg, Germany. 5. Medical Sociology, Department of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany.
Abstract
INTRODUCTION: Epidemiologic research in female sexual dysfunction (FSD) has gained momentum in recent years, particularly in clinical populations and in menopausal women. However, sexual dysfunction also affects premenopausal women in general populations. Previous literature reviews have been unable to quantify the burden of FSD in general populations. This has been due in part to different definitions of dysfunction, heterogeneous study design, and the wide variety of measurement tools used. AIM: To provide a meta-analytical estimate of the prevalence of FSD in premenopausal women. METHODS: Observational studies that assessed the prevalence of FSD in premenopausal women were systematically sought in relevant databases (January 2000 through July 2014). Publications that reported the prevalence rate for at least one domain of FSD were included. A meta-analysis of prevalence rates was performed and a meta-regression was used to analyze factors of study design. MAIN OUTCOME MEASURES: Estimated prevalence rates of FSD and its domains (hypoactive sexual desire disorder, sexual aversion disorder, female sexual arousal disorder, lubrication difficulties, female orgasmic disorder, and pain disorders). RESULTS: After screening 9,292 results, 440 publications were retrieved for full-text review. Of these, 135 studies were included in the systematic review. Ninety-five of these studies were assessed further in a meta-analysis. There was substantial heterogeneity among studies. The prevalence of FSD in premenopausal women was estimated to be 40.9% (95% CI = 37.1-44.7, I2 = 99.0%). Prevalence rates of individual sexual disorders ranged from 20.6% (lubrication difficulties) to 28.2% (hypoactive sexual desire disorder). Further analyses showed significantly higher rates of FSD in studies in Africa, studies that used non-validated assessment tools, and studies without pharmaceutical funding. CONCLUSION: Prevalence estimates of FSD vary substantially. Nonetheless, results show that FSD is a significant public health problem that affects 41% of premenopausal women around the globe. More research and improved standardization are needed in this field.
INTRODUCTION: Epidemiologic research in female sexual dysfunction (FSD) has gained momentum in recent years, particularly in clinical populations and in menopausal women. However, sexual dysfunction also affects premenopausal women in general populations. Previous literature reviews have been unable to quantify the burden of FSD in general populations. This has been due in part to different definitions of dysfunction, heterogeneous study design, and the wide variety of measurement tools used. AIM: To provide a meta-analytical estimate of the prevalence of FSD in premenopausal women. METHODS: Observational studies that assessed the prevalence of FSD in premenopausal women were systematically sought in relevant databases (January 2000 through July 2014). Publications that reported the prevalence rate for at least one domain of FSD were included. A meta-analysis of prevalence rates was performed and a meta-regression was used to analyze factors of study design. MAIN OUTCOME MEASURES: Estimated prevalence rates of FSD and its domains (hypoactive sexual desire disorder, sexual aversion disorder, female sexual arousal disorder, lubrication difficulties, female orgasmic disorder, and pain disorders). RESULTS: After screening 9,292 results, 440 publications were retrieved for full-text review. Of these, 135 studies were included in the systematic review. Ninety-five of these studies were assessed further in a meta-analysis. There was substantial heterogeneity among studies. The prevalence of FSD in premenopausal women was estimated to be 40.9% (95% CI = 37.1-44.7, I2 = 99.0%). Prevalence rates of individual sexual disorders ranged from 20.6% (lubrication difficulties) to 28.2% (hypoactive sexual desire disorder). Further analyses showed significantly higher rates of FSD in studies in Africa, studies that used non-validated assessment tools, and studies without pharmaceutical funding. CONCLUSION: Prevalence estimates of FSD vary substantially. Nonetheless, results show that FSD is a significant public health problem that affects 41% of premenopausal women around the globe. More research and improved standardization are needed in this field.
Authors: Bianca Escuer Bifani; Tatiana de Oliveira Sato; Gabriel Bernardi Dos Santos; Paula Regina Mendes da Silva Serrão; Ana Paula Rodrigues Rocha; Cristiano Carvalho Journal: Int Urogynecol J Date: 2022-08-01 Impact factor: 1.932
Authors: Peer Briken; Silja Matthiesen; Laura Pietras; Christian Wiessner; Verena Klein; Geoffrey M Reed; Arne Dekker Journal: Dtsch Arztebl Int Date: 2020-09-25 Impact factor: 5.594
Authors: Justin M Dubin; W Austin Wyant; Navin C Balaji; Iakov V Efimenko; Quinn C Rainer; Belen Mora; Lisa Paz; Ashley G Winter; Ranjith Ramasamy Journal: Sex Med Date: 2021-05-29 Impact factor: 2.491